PriceTargets.com logo

Albireo Pharma - ALBO Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $44.40
  • Forecasted Upside: 0.57%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$44.15 As of 03/2/2023 05:00 PM ET
▼ -0.1 (-0.23%)
Get New Albireo Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALBO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALBO

Analyst Price Target is $44.40
▲ +0.57% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Albireo Pharma in the last 3 months. The average price target is $44.40, with a high forecast of $48.00 and a low forecast of $42.00. The average price target represents a 0.57% upside from the last price of $44.15.

This chart shows the closing price for ALBO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 investment analysts is to hold stock in Albireo Pharma. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/15/2023HC WainwrightReiterated RatingNeutral$42.00Low
1/11/2023GuggenheimDowngradeBuy ➝ NeutralLow
1/11/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$49.00 ➝ $42.00Low
1/11/2023CowenDowngradeOutperform ➝ Market Perform$68.00 ➝ $48.00Low
1/11/2023CowenDowngradeMarket Perform$68.00 ➝ $48.00Low
1/10/2023HC WainwrightDowngradeBuy ➝ Neutral$42.00Low
1/9/2023WedbushDowngradeOutperform ➝ Neutral$53.00 ➝ $42.00Low
10/13/2022GuggenheimBoost Target$59.00Low
10/12/2022HC WainwrightBoost TargetBuy$54.00 ➝ $68.00Low
10/12/2022Robert W. BairdBoost TargetOutperform$43.00 ➝ $55.00Low
9/23/2022Robert W. BairdBoost Target$40.00 ➝ $43.00Low
9/8/2022GuggenheimInitiated CoverageBuy$55.00Low
8/16/2022WedbushLower TargetOutperform$72.00 ➝ $61.00Low
8/16/2022HC WainwrightLower TargetBuy$80.00 ➝ $54.00Low
8/16/2022Robert W. BairdLower TargetOutperform$66.00 ➝ $40.00Low
5/17/2022WedbushReiterated RatingBuy$72.00High
5/17/2022Robert W. BairdLower Target$72.00 ➝ $66.00High
3/28/2022WedbushInitiated CoverageOutperform$75.00Medium
12/20/2021WedbushReiterated RatingBuy$84.00Medium
11/5/2021HC WainwrightBoost TargetBuy$79.00 ➝ $80.00High
10/14/2021Robert W. BairdReiterated RatingBuy$72.00High
9/16/2021WedbushBoost TargetOutperform$82.00 ➝ $84.00Low
9/8/2021HC WainwrightReiterated RatingBuy$79.00High
7/22/2021Robert W. BairdBoost TargetOutperform$67.00 ➝ $72.00High
7/21/2021WedbushBoost TargetOutperform$73.00 ➝ $82.00High
7/21/2021HC WainwrightBoost TargetBuy$76.00 ➝ $79.00Low
3/26/2021Jefferies Financial GroupBoost TargetPositive ➝ Buy$79.00 ➝ $82.00High
3/1/2021Piper SandlerBoost TargetOverweight$68.00 ➝ $81.00Low
3/1/2021Robert W. BairdReiterated RatingBuy$67.00Low
12/18/2020HC WainwrightBoost TargetBuy$67.00 ➝ $75.00High
11/19/2020WedbushReiterated RatingBuy$66.00Low
9/18/2020WedbushReiterated RatingBuy$62.00High
9/10/2020CowenBoost Target$39.00 ➝ $65.00Medium
9/8/2020Jefferies Financial GroupBoost TargetPositive ➝ Buy$50.00 ➝ $79.00High
9/8/2020Needham & Company LLCBoost TargetBuy$50.00 ➝ $68.00High
9/8/2020HC WainwrightBoost TargetPositive ➝ Buy$50.00 ➝ $67.00High
9/8/2020Piper SandlerBoost TargetOverweight$45.00 ➝ $81.00High
8/19/2020HC WainwrightLower TargetBuy$64.00 ➝ $50.00High
8/10/2020William BlairReiterated RatingBuyLow
7/30/2020Piper SandlerInitiated CoverageOverweight$45.00High
7/28/2020Needham & Company LLCReiterated RatingBuy$50.00Medium
7/27/2020CowenReiterated RatingOutperform$39.00Medium
7/16/2020HC WainwrightBoost TargetBuy$62.00 ➝ $64.00Medium
6/24/2020Robert W. BairdInitiated CoverageOutperform$52.00High
6/17/2020WedbushReiterated RatingOutperformHigh
6/16/2020Needham & Company LLCInitiated CoverageBuy$50.00Medium
6/14/2020HC WainwrightReiterated RatingBuy$62.00Medium
5/11/2020WedbushReiterated RatingBuy$60.00High
5/7/2020Needham & Company LLCInitiated CoverageBuy$50.00High
4/5/2020HC WainwrightReiterated RatingBuy$62.00High
3/5/2020CowenReiterated RatingBuy$39.00Low
3/3/2020HC WainwrightReiterated RatingBuy$62.00High
3/3/2020WedbushLower TargetOutperform$69.00 ➝ $60.00High
1/30/2020HC WainwrightReiterated RatingBuy$62.00High
11/6/2019CowenReiterated RatingBuy$39.00Low
11/6/2019WedbushReiterated RatingBuy$69.00Low
8/11/2019HC WainwrightReiterated RatingBuy$62.00Medium
8/9/2019WedbushReiterated RatingOutperform$69.00High
7/15/2019William BlairReiterated RatingBuyLow
7/11/2019WedbushSet TargetBuy$69.00Medium
7/10/2019HC WainwrightReiterated RatingBuy$62.00High
5/23/2019WedbushSet TargetBuy$69.00Low
5/9/2019William BlairReiterated RatingOutperformHigh
4/17/2019CowenReiterated RatingBuyHigh
3/10/2019WedbushSet TargetBuy$69.00High
2/28/2019HC WainwrightInitiated CoverageBuy ➝ Buy$62.00High
1/25/2019WedbushReiterated RatingBuy$69.00Low
(Data available from 12/5/2018 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Albireo Pharma logo
Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.
Read More

Today's Range

Now: $44.15
Low: $43.99
High: $44.90

50 Day Range

MA: $44.17
Low: $43.50
High: $44.95

52 Week Range

Now: $44.15
Low: $16.02
High: $45.23

Volume

1,241,200 shs

Average Volume

704,539 shs

Market Capitalization

$913.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03

Frequently Asked Questions

What sell-side analysts currently cover shares of Albireo Pharma?

The following Wall Street analysts have issued reports on Albireo Pharma in the last year: Cowen Inc, Cowen Inc., Guggenheim, HC Wainwright, Jefferies Financial Group Inc., StockNews.com, and Wedbush.
View the latest analyst ratings for ALBO.

What is the current price target for Albireo Pharma?

5 Wall Street analysts have set twelve-month price targets for Albireo Pharma in the last year. Their average twelve-month price target is $44.40, suggesting a possible upside of 0.6%. Cowen Inc. has the highest price target set, predicting ALBO will reach $48.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $42.00 for Albireo Pharma in the next year.
View the latest price targets for ALBO.

What is the current consensus analyst rating for Albireo Pharma?

Albireo Pharma currently has 6 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ALBO, but not buy more shares or sell existing shares.
View the latest ratings for ALBO.

What other companies compete with Albireo Pharma?

Other companies that are similar to Albireo Pharma include Akero Therapeutics, Keros Therapeutics, MannKind, Ardelyx and Alpine Immune Sciences. Learn More about companies similar to Albireo Pharma.

How do I contact Albireo Pharma's investor relations team?

Albireo Pharma's physical mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company's listed phone number is (857) 254-5555 and its investor relations email address is shar[email protected]. The official website for Albireo Pharma is www.albireopharma.com. Learn More about contacing Albireo Pharma investor relations.